Multiple System Atrophy: Clinical Features and Management

[1]  D. Brooks.  Neuroimaging in Parkinson’s disease , 2004, NeuroRX.

[2]  Klaus Seppi,et al.  Proposed neuroimaging criteria for the diagnosis of multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[3]  Y. Agid,et al.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study , 2008, Brain : a journal of neurology.

[4]  Aldo Quattrone,et al.  Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[6]  Günther Deuschl,et al.  Red flags for multiple system atrophy , 2008, Movement disorders : official journal of the Movement Disorder Society.

[7]  Matthias Reimold,et al.  The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study , 2008, The Lancet Neurology.

[8]  K. Ito,et al.  Cognitive impairments in multiple system atrophy , 2008, Neurology.

[9]  M. S. Lee,et al.  Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. , 2008, Brain : a journal of neurology.

[10]  M. T. Pellecchia,et al.  The arginine growth hormone stimulation test in bradykinetic‐rigid parkinsonisms , 2008, Movement disorders : official journal of the Movement Disorder Society.

[11]  C. Mathias.  L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension , 2008, Clinical Autonomic Research.

[12]  W. Poewe,et al.  Diffusion weighted imaging best discriminates PD from MSA‐P: A comparison with tilt table testing and heart MIBG scintigraphy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[13]  Á. Iranzo.  Sleep and breathing in multiple system atrophy , 2007, Current treatment options in neurology.

[14]  E. Tolosa,et al.  Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .

[15]  Karsten Specht,et al.  Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy—A comparison between clinical subtypes and correlations with clinical parameters , 2007, NeuroImage.

[16]  Tetsutaro Ozawa,et al.  Daytime hypoxemia, sleep-disordered breathing, and laryngopharyngeal findings in multiple system atrophy. , 2007, Archives of neurology.

[17]  W. F. Abdo,et al.  CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease , 2007, Neurobiology of Aging.

[18]  C. Fowler.  Update on the neurology of Parkinson's disease , 2007, Neurourology and urodynamics.

[19]  C. Mathias,et al.  Progression of dysautonomia in multiple system atrophy: a prospective study of self‐perceived impairment , 2007, European journal of neurology.

[20]  Michael Schocke,et al.  Progression of brain atrophy in multiple system atrophy , 2007, Journal of Neurology.

[21]  M. T. Pellecchia,et al.  Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. , 2006, Clinical medicine & research.

[22]  P. Schestatsky,et al.  Evaluation of sympathetic skin response in Parkinson's disease. , 2006, Parkinsonism & related disorders.

[23]  H. Sasaki,et al.  MSA-C is the predominant clinical phenotype of MSA in Japan: Analysis of 142 patients with probable MSA , 2006, Journal of the Neurological Sciences.

[24]  M. T. Pellecchia,et al.  Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test , 2006, Annals of neurology.

[25]  S. Gilman,et al.  PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  F. Holsboer,et al.  Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. , 2006, Parkinsonism & related disorders.

[27]  Francesco Fera,et al.  Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.

[28]  M. Kawamata,et al.  Non-invasive positive pressure ventilation for laryngeal contraction disorder during sleep in multiple system atrophy , 2006, Journal of the Neurological Sciences.

[29]  W. F. Abdo,et al.  CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia , 2006, Neurology.

[30]  Klaus Seppi,et al.  Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. , 2006, Archives of neurology.

[31]  W. Poewe,et al.  Levodopa‐induced sleepiness in the Parkinson variant of multiple system atrophy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[32]  José Luis Molinuevo,et al.  Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study , 2006, The Lancet Neurology.

[33]  M. T. Pellecchia,et al.  Health‐related quality of life in multiple system atrophy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[34]  Vonck Kristl,et al.  Deep brain stimulation of the internal pallidum in multiple system atrophy. , 2006 .

[35]  P Sandroni,et al.  Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease , 2006, Neurology.

[36]  M. T. Pellecchia,et al.  Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) , 2006, Movement disorders : official journal of the Movement Disorder Society.

[37]  D. Berg,et al.  Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations , 2006, Ultraschall in der Medizin.

[38]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[39]  C. Mathias,et al.  l-threo-dihydroxyphenylserine (l-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: A multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure , 2001, Clinical Autonomic Research.

[40]  Peripheral neuropathy as the presenting feature of multiple system atrophy , 2001, Clinical Autonomic Research.

[41]  Yoav Ben-Shlomo,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Clinical Autonomic Research.

[42]  D. Berg.  Transcranial sonography in the early and differential diagnosis of Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[43]  J. Trojanowski,et al.  The North American Multiple System Atrophy Study Group , 2005, Journal of Neural Transmission.

[44]  N. Quinn,et al.  Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis , 2005, Movement disorders : official journal of the Movement Disorder Society.

[45]  J. Seibyl,et al.  The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. , 2005, Minerva medica.

[46]  Shinn-Zong Lin,et al.  Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T. , 2005, AJNR. American journal of neuroradiology.

[47]  G. Wenning.  Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy , 2005, Clinical neuropharmacology.

[48]  B. Bioulac,et al.  Sleep disorders in multiple system atrophy , 2005, Journal of Neural Transmission.

[49]  A. Schrag,et al.  Depressive symptoms and life satisfaction in patients with multiple system atrophy , 2005, Movement disorders : official journal of the Movement Disorder Society.

[50]  N. Quinn,et al.  How to diagnose multiple system atrophy , 2005, Movement disorders : official journal of the Movement Disorder Society.

[51]  P. S. Mathuranath,et al.  Subcortical dementia revisited: Similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) , 2005, Neurocase.

[52]  Klaus Seppi,et al.  An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism , 2005, Current opinion in neurology.

[53]  M. T. Pellecchia,et al.  The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. , 2005, Brain : a journal of neurology.

[54]  F. Kopper,et al.  The European Multiple System Atrophy-Study Group (EMSA-SG) , 2005, Journal of Neural Transmission.

[55]  E. Tolosa,et al.  Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD , 2005, Neurology.

[56]  M. Schocke,et al.  How to diagnose MSA early: the role of magnetic resonance imaging , 2005, Journal of Neural Transmission.

[57]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[58]  Klaus Seppi,et al.  Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.

[59]  A. Lees,et al.  Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. , 2005, Brain : a journal of neurology.

[60]  M. T. Pellecchia,et al.  Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late‐onset cerebellar ataxia , 2005, Clinical endocrinology.

[61]  D. Berg,et al.  Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[62]  Y. Katayama,et al.  Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[63]  Klaus Seppi,et al.  Progression of parkinsonism in multiple system atrophy , 2005, Journal of Neurology.

[64]  Werner Jaschke,et al.  Comparison of diffusion‐weighted imaging and [123I]IBZM‐SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[65]  N. Quinn,et al.  Occupational therapy in multiple system atrophy: A pilot randomized controlled trial , 2004, Movement disorders : official journal of the Movement Disorder Society.

[66]  Yih-Ru Wu,et al.  Sensory neuropathy as the initial manifestation of multiple system atrophy. , 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

[67]  J. Zarranz,et al.  Parkinson's disease‐like presentation of multiple system atrophy with poor response to STN stimulation: A clinicopathological case report , 2004, Movement disorders : official journal of the Movement Disorder Society.

[68]  Christian Kremser,et al.  Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease , 2004, NeuroImage.

[69]  A. Lees,et al.  The l-dopa response in vascular parkinsonism , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  Carlo Colosimo,et al.  Multiple system atrophy , 2004, The Lancet Neurology.

[71]  M. Merello,et al.  Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study , 1996, Journal of Neurology.

[72]  H. Kaufmann,et al.  Autonomic failure in neurodegenerative disorders. , 2003, Seminars in neurology.

[73]  C. Fowler,et al.  Investigation and management of neurogenic bladder dysfunction , 2003, Journal of neurology, neurosurgery, and psychiatry.

[74]  C. Fowler,et al.  Evaluation and Treatment of Autonomic Disorders of the Urogenital System , 2003, Seminars in neurology.

[75]  W. Poewe,et al.  The ‘risus sardonicus’ of multiple system atrophy , 2003, Movement Disorders.

[76]  Werner Poewe,et al.  Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[77]  C. Büchel,et al.  Voxel‐based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy , 2003, Movement disorders : official journal of the Movement Disorder Society.

[78]  R B Banati,et al.  [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy , 2003, Neurology.

[79]  O. Rascol,et al.  Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[80]  K. Kirchhof,et al.  Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study , 2003, International Journal of Impotence Research.

[81]  W. Oertel,et al.  Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type , 2003, Movement disorders : official journal of the Movement Disorder Society.

[82]  Yasin Temel,et al.  Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy--parkinsonism. Report of four cases. , 2003, Journal of neurosurgery.

[83]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[84]  B U Meyer,et al.  Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes , 2002, Neurology.

[85]  D. Riley,et al.  Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[86]  C. Colosimo,et al.  The symptomatic treatment of multiple system atrophy , 2002, European journal of neurology.

[87]  J. Dichgans,et al.  The aetiology of sporadic adult-onset ataxia. , 2002, Brain : a journal of neurology.

[88]  Y. Abe,et al.  Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. , 2002, Brain : a journal of neurology.

[89]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[90]  Masanori Ichise,et al.  Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP , 2002, Movement disorders : official journal of the Movement Disorder Society.

[91]  W. Poewe,et al.  Dystonia in multiple system atrophy , 2002, Journal of neurology, neurosurgery, and psychiatry.

[92]  E. Alfonsi,et al.  Not paralysis, but dystonia causes stridor in multiple system atrophy , 2002, Neurology.

[93]  Robert B. Innis,et al.  [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .

[94]  I. Hussain,et al.  Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension , 2001, Journal of neurology, neurosurgery, and psychiatry.

[95]  B. Boeve,et al.  Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy , 2001, Movement disorders : official journal of the Movement Disorder Society.

[96]  E. Broussolle,et al.  Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy , 2001, Movement disorders : official journal of the Movement Disorder Society.

[97]  M. Skalej,et al.  Sporadic cerebellar ataxia associated with gluten sensitivity. , 2001, Brain : a journal of neurology.

[98]  M Zappia,et al.  Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[99]  I Litvan,et al.  Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.

[100]  O. Rascol,et al.  Orthostatic Hypotension in Patients with Parkinson’s Disease , 2001, Drugs & aging.

[101]  W. Poewe,et al.  Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia , 2002, Journal of Neurology.

[102]  N. Accornero,et al.  Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure , 2000, Movement disorders : official journal of the Movement Disorder Society.

[103]  L. Deecke,et al.  [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[104]  C. Clarke,et al.  Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[105]  E. Tolosa,et al.  Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy , 2000, The Lancet.

[106]  S. Gilman,et al.  Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy , 2000, Neurology.

[107]  M. Silber,et al.  Stridor and death in multiple system atrophy , 2000, Movement disorders : official journal of the Movement Disorder Society.

[108]  Nir Giladi,et al.  Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease , 2000 .

[109]  N P Quinn,et al.  What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[110]  R. Sakakibara,et al.  Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. , 2000, Journal of the autonomic nervous system.

[111]  R. Sakakibara,et al.  Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[112]  C. Lücking,et al.  Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy , 1999, Neurology.

[113]  J. Dichgans,et al.  Cerebellar ataxia with glutamic acid decarboxylase autoantibodies , 1999, Neurology.

[114]  J. Jordan,et al.  Contrasting actions of pressor agents in severe autonomic failure. , 1998, The American journal of medicine.

[115]  K. Nakajima,et al.  Decreased myocardial 123 I‐MIBG uptake in Parkinson's disease , 1998, Acta neurologica Scandinavica.

[116]  T Klockgether,et al.  The natural history of degenerative ataxia: a retrospective study in 466 patients. , 1998, Brain : a journal of neurology.

[117]  D. Radice,et al.  Cognitive dysfunction and impaired organization of complex motility in degenerative parkinsonian syndromes. , 1998, Archives of neurology.

[118]  W. Oertel,et al.  123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[119]  D J Brooks,et al.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.

[120]  S. Hirai,et al.  [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy]. , 1997, Rinsho shinkeigaku = Clinical neurology.

[121]  R. Freeman,et al.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. , 1997, JAMA.

[122]  N. Quinn,et al.  Survival of patients with pathologically proven multiple system atrophy , 1997, Neurology.

[123]  C. Marsden,et al.  Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. , 1997, Brain : a journal of neurology.

[124]  Mark W. Mahowald,et al.  Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder , 1996, Neurology.

[125]  C D Marsden,et al.  Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. , 1995, Brain : a journal of neurology.

[126]  K. Ito,et al.  A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. , 1995, Journal of the autonomic nervous system.

[127]  Y. Agid,et al.  “Pure” striatonigral degeneration and Parkinson's disease: A comparative clinical study , 1995, Movement disorders : official journal of the Movement Disorder Society.

[128]  N P Quinn,et al.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. , 1994, Brain : a journal of neurology.

[129]  C. Fowler,et al.  Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. , 1994, The Journal of urology.

[130]  C Trenkwalder,et al.  123I‐Iodobenzamide‐SPECT in 83 patients with de novo parkinsonism , 1993, Neurology.

[131]  A. Churchyard,et al.  Dopa resistance in multiple‐system atrophy: Loss of postsynaptic D2 receptors , 1993, Annals of neurology.

[132]  J. Jankovic,et al.  Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. , 1993, The American journal of medicine.

[133]  W. Kuhn,et al.  Long-term observation of chronic subsutaneous administration of lisuride in the treatment of motor fluctuations in parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[134]  W. Oertel,et al.  Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. , 1992, Archives of neurology.

[135]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[136]  A. Lees,et al.  Challenge tests to predict the dopaminergic response in untreated Parkinson's disease , 1991, Neurology.

[137]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[138]  N. Quinn,et al.  Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[139]  C. Mathias,et al.  The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. , 1986, British medical journal.

[140]  R. Bannister,et al.  Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[141]  C. Tanner,et al.  Bupropion in Parkinson's disease , 1984, Neurology.

[142]  A. Lees,et al.  The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). , 1981, Journal of neurology, neurosurgery, and psychiatry.

[143]  I. Kopin,et al.  Pharmacologic distinction of different orthostatic hypotension syndromes , 1981, Neurology.

[144]  I. Kopin,et al.  The sympathetic-nervous-system defect in primary orthostatic hypotension. , 1977, The New England journal of medicine.